Device Jagtome_endo

Jagtome Rx 39

Payments companies reported to CMS as associated with Jagtome Rx 39. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1,144associated payments (2023-2025)
41clinicians with associated payments
1company reporting

By year

2023 $366
2024 $447
2025 $331

Payments reported as associated with Jagtome Rx 39, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Gastroenterology (Internal Medicine) $908
Internal Medicine $90.11
Adolescent Medicine (Pediatrics) $26.49
Diagnostic Radiology $21.33
Infectious Disease $20.96
Gerontology (Nurse Practitioner) $13.09

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Jagtome Rx 39

These are the largest totals companies reported as associated with Jagtome Rx 39. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Thaer Abdelfattah Providence, RI Gastroenterology (Internal Medicine) $101.54
Benjamin Hewitt Dothan, AL Gastroenterology (Internal Medicine) $72.81
Fazel Dinary Centerville, OH Gastroenterology (Internal Medicine) $51.20
Omar Sadiq Parma, OH Gastroenterology (Internal Medicine) $51.20
John Trillo Brooklyn, NY Gastroenterology (Internal Medicine) $43.38
Amy Hosmer Pittsburgh, PA Gastroenterology (Internal Medicine) $43.38
Sara Samad Neptune, NJ Gastroenterology (Internal Medicine) $43.37
Samiran Roy Chaudhury Brooklyn, NY Internal Medicine $43.37
Michael Bernstein Brooklyn, NY Gastroenterology (Internal Medicine) $43.37
Muhammad Abdullah Brooklyn, NY Gastroenterology (Internal Medicine) $43.37

Prescribed Jagtome Rx 39?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.